AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Imugene has formed a partnership with clinical-stage biopharmaceutical firm – RenovoRx for its oncolytic virus therapy.
- The collaboration will assess the ability to administer the CF33 oncolytic virus technology with the TAMP therapy platform of RenovoRx.
- Following the update, shares of Imugene jumped 4.76% to trade at AU$0.11 per share.
ASX-listed Imugene Limited (ASX: IMU) has announced a strategic research collaboration with RenovoRx, Inc. (Nasdaq: RNXT) to deliver the former’s oncolytic virus therapy by employing the latter’s proprietary Trans-Arterial Micro-Perfusion (TAMP) platform.
The collaboration is expected to enable the targeted delivery of CF33 oncolytic virus to liver, pancreatic and other difficult-to-access tumours.
RenovoRx is a clinical-stage biopharmaceutical company which develops targeted combination therapies for unmet medical demands.
The collaboration will be financed from existing budgets and resources for up to four months. If successful, the companies intend to expand the partnership.
IMU shares jump
Triggered by the update, Imugene’s stock registered a gain of 4.76% to trade at AU$0.11 apiece at the time of writing on 20 July 2023.
Treating difficult-to-access tumours
CF33 trans-arterially is expected to be valuable to cancer patients compared to traditional administration methods, highlights the company update. The traditional methods of administration have been found to limit therapy uptake, as dense fibrous tissue and lack of blood vessels supply the tumours.
In a study, the TAMP platform has indicated a 100-fold increase in local tissue concentration compared to conventional IV delivery as well as advantages compared to off-the-shelf intra-arterial delivery.
IMU highlighted in its update that TAMP’s differentiated approach to treatment delivery presents the potential to boost an oncology therapy’s efficacy, widen its therapeutic window and improve safety by focusing its distribution uniformly in the target tissue.